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RESEARCH ARTICLE
3,30-Diindolylmethane enhances apoptosis in docetaxel-treated breast cancer cells
by generation of reactive oxygen species
Susan Lanza-Jacoby and Guanjun Cheng
Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA
ABSTRACT
Context: A major problem in the treatment of cancer is the development of toxic side effects and
resistance to chemotherapy. The use of plant compounds to overcome resistance and prevent toxicity is
a potential strategy for treatment.
Objective: We evaluated whether 3,30-diindolylmethane (DIM) enhanced the sensitivity of breast cancer
cells to docetaxel (DOC).
Materials and methods: MDA-MB231 and Sk-BR-3 cells were treated with and without 25 or 50mM of
DIM and 1nM of DOC for 48 and 72h, respectively. MTT assay was used to measure cell survival.
Apoptosis and intracellular reactive oxygen species (ROS) were determined by flow cytometry. The
expression of proteins regulating ROS production and apoptosis was evaluated by immunoblot-
ting technique.
Results: Combining 25mM of DIM with 1 nM DOC decreased cell survival by 42% in MDA-MB231 cells
and 59% in Sk-BR-3 cells compared to control, DIM, or DOC (p 0.05). The combination treatment
increased apoptosis over 20% (p 0.01) in both cell lines, which was associated with decreased Bcl-2,
increased Bax, cleaved PARP and activated JNK (p 0.01). ROS production increased by 46.5% in the
MDA-MB231 and 29.3% in Sk-BR-3 cells with the combination compared to DIM or DOC alone.
Pretreating cells with N-acetyl-cysteine or Tiron abrogated the anti-survival effect of the combination. The
increase in ROS was associated with a 54% decrease in MnSOD and 47% increase in NOX2 protein com-
pared to the other groups.
Conclusions: Our findings indicated that DIM enhances the sensitivity of breast cancer cells to DOC treat-
ment by increasing ROS, which led to decreased cell survival and apoptosis.
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Numerous studies have demonstrated the protective effects of
dietary components in vegetables for cancer prevention.
Although supplement use has been increased in cancer patients
in recent years, there is very little information regarding the
effect of these compounds during chemotherapy. Indole-3-carbi-
nol (I3C) is one such naturally occurring active component of
cruciferous vegetables. The crushing or mechanical chewing of
the vegetable releases plant enzymes that break down the glucosi-
nolates found in all cruciferous vegetables to I3C, which, in turn,
is further broken down in the acidic pH of the stomach to sev-
eral condensed products including 3,30-diindolylmethane (DIM).
Plasma from humans fed with I3C supplements contains DIM
and not I3C, which suggests that DIM is the active component
that reaches the cells (Bell et al. 2000). DIM supplements are
commercially available and inexpensive. I3C and DIM have been
shown to protect against cancers of prostate (Chinni et al. 2001),
cervix (Chen et al. 2001), breast (Hong et al. 2002), colon (Kim
et al. 2009), pancreas (Azmi et al. 2008) and lung (Kassie et al.
2007). Studies have demonstrated that DIM inhibits proliferation,
cell cycle and induces apoptosis in estrogen receptor negative
(ER–) and ER positive (ERþ) breast cancer cells (Hong et al.
2002). DIM was found to inhibit tumor growth by regulating
nuclear factor-jB (NF-jB) (Rahman and Sarkar 2005), FOXM1
(Ahmad et al. 2011) cdk6 and p21 (Firestone and Bjeldanes
2003). Previous studies have also shown that DIM induced
stress-activated pathways including activating JNK kinase, which
are important in regulating cell growth and apoptosis (Xue et al.
2005; Gong et al. 2006). These studies have identified a role for
oxidative stress by DIM in mediating G2 cell cycle arrest (Chen
et al. 1998), decreasing ATP synthase leading to the induction of
p21 (Gong et al. 2006) and inhibiting FOF-ATP synthase result-
ing in depletion of ATP and induction of ROS (Roy et al. 2008).
Docetaxel (DOC) is the most widely used taxane for the treat-
ment of several cancers including breast, lung, squamous cell car-
cinoma of the head and neck, ovary and the prostate. Considering
that DOC is more toxic than paclitaxel and is very often adminis-
tered with other chemotherapeutic drugs, the problem of toxicity
increases with many patients experiencing unpleasant side effects.
There are reports which indicate that the plant compounds such
as curcumin (Bayet-Robert et al. 2010), green tea (Luo et al. 2010)
and resveratrol (Al-Abd et al. 2011) increase the sensitivity of
breast cancers to DOC with the potential for reducing toxicity. In
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an earlier study, we showed that DIM enhanced apoptosis in
paclitaxel-treated 435eB1 breast cancer cells (McGuire et al. 2006).
Our findings were confirmed by other reports (Rahman et al.
2007; Ahmad et al. 2011). However, the mechanism by which
DIM enhances the anticancer effect of taxanes in breast cancer is
not well understood. Previous studies have demonstrated that the
treatment of cancer cells with DIM induced ROS production
(Gong et al. 2006; Kandala and Srivastava 2010; Wang et al.
2016). Considering these observations, we investigated whether
ROS is a mechanism by which DIM sensitizes breast cancer cells
to the chemotherapeutic agent, DOC.
Materials and methods
Cell culture and reagents
The human breast cancer cell lines MDA-MB231 and SK-BR-3
were obtained from American Type Culture Collection (ATCC),
Manassas, VA. MDA-MB231 cells are a triple negative, highly
aggressive cell line and SK-BR-3 cells are ER- and overexpress
HER-2. Cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 1X penicillin/streptomycin and
supplemented with 10% fetal bovine serum (Atlantic Biologicals,
Miami, FL) in a humidified atmosphere with 5% CO2 at 37 C.
To remove the adherent cells from the flasks for passaging or
counting, cells were washed with Hanks’ balanced salt solution
without calcium or magnesium, then the cells were incubated
with a small volume of 0.25% trypsin-EDTA (Sigma Chemical
Co., St. Louis, MO) for 5–10min and washed with culture
medium by centrifugation. We obtained BioResponse DIM from
Michael Zelsnick, Bio Response, Boulder, CO and DOC was
obtained from Aventis Pharmaceuticals, Bridgewater, NJ.
For immunoblot analysis, the following antibodies were used:
Bcl-2, Bax, poly-ADP-ribose polymerases (PARP), cleaved PARP,
JNK, phosphorylated JNK (Cell Signaling Technology, Beverly,
MA), MnSOD (Santa Cruz, Santa Cruz, CA), NOX4 and NOX2
(Novus Biologicals, Littleton, CO) and GAPDH (Millipore Corp.,
Billerica, MA).
Cell viability
The viability of cells was determined by the mitochondrial reduc-
tase activity as an indicator of viable cells; assays were conducted
with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) reduction assay. Cells were seeded on 96-well plates
at a density of 1 104 cells/well and allowed to adhere for 24 h.
Then, the cells were incubated with DIM, DOC, or their combi-
nations. After the required incubation time, the wells were vac-
uumed and treated with 0.25mg/mL MTT dissolved in DMSO
for 3 h at 37 C. A microplate reader was used to measure the
absorbance at a wavelength of 570 nm.
Immunoblotting
Cells were washed with cold PBS and harvested by scraping into
0.2mL of RIPA buffer containing 50mM Tris-HCl (pH 7.4),
150mM NaCl, 1% NP40, 1mM EDTA, 0.25% sodium deoxycho-
late, 1mM NaF, 10 mM Na3VO4, 1mM phenylmethysulfonyl
fluoride and protease inhibitor cocktail (Sigma Chemical Co, St
Louis, MO, catalog # P7626 and P8340) according to man-
ufacturer’s instructions. Protein concentration of cell lysates was
determined by using a Bio-Rad protein assay (Bio-Rad, Hercules,
CA). Proteins were denatured by heat at 95 C and separated by
3–8% NuPAGE gel or 4–12% NuPAGE and transferred to a
nitrocellulose membrane and nonspecific binding was blocked
with 5% dry milk in TBST (40mM Tris-Cl, pH 7.6, 150mM,
NaCl, 0.2% Tween-20) for 1 h at room temperature. With con-
stant shaking, membranes were incubated with primary anti-
bodies overnight at 4 C. After washing with TBST three times,
the membranes were incubated with secondary antibodies at
room temperature for 1 h with constant shaking. The expres-
sion of the targeted proteins was detected using an ECL kit
(Amersham Biosciences, Marlborough, MA) following man-
ufacturer’s instructions and visualized by autoradiography
with Hyperfilm.
Annexin V-FITC staining
Apoptotic cells were quantified using the annexin V plus propi-
dium Iodide Apoptosis detection kit (R & D Systems,
Minneapolis, MN) according to manufacturer’s instructions.
Approximately 5 105 cells were resuspended in 100mL of the
manufacturer-supplied 1x binding buffer and mixed with 1mL of
annexin V-FITC and 10 mL of propidium iodide. After 15min of
incubation in the dark at room temperature, 400mL of 1x bind-
ing buffer was added and the cells were analyzed using a BD
FACS flow cytometer. Annexin V detects cellular apoptosis,
while propidium iodide detects necrotic or late apoptotic cells.
Measurement of ROS production
Prooxidant levels (H2O2) were measured by labeling cells for
15min at 37 C using oxidation sensitive [C-400; 5- (and-6)-car-
boxy-20,70-dichlorodihydrofluorescein diacetate (DCFDA)
Molecular Probes, Eugene, OR] and evaluating the conversion to
[C-369; 5-(and-6)-carboxy-20,70-dichlorofluorescein diacetate]
(DCF), a fluorescent dye. Cells were seeded into six-well culture
plates at a density of 5 105/mL and treated for 24 or 48 h with
the indicated concentrations of DIM with and without DOC. For
analysis, cells were trypsinized, washed in warm PBS, incubated
with 10 mM DCFDA for 30min and analyzed by BD FACS flow
cytometer. In some experiments the antioxidant, N-acetyl cyst-
eine (NAC) or Tiron (superoxide scavenger) were added to the
cells that were pretreated for 1 h with either 5mM NAC or
1mM Tiron and incubated for 24 or 48 h.
Statistical analysis
Results are expressed as mean± SE of 3–4 different experiments.
Statistical analysis was performed using one or two-way ANOVA
followed by the Bonferroni post-hoc test using SAS 9.3 software
analysis (SAS Institute, Cary, NC, USA).
Results
DIM in combination with DOC decreased the viability of
human breast cancer cells
MDA-MB231 and Sk-BR-3 cells were incubated with DIM (25 or
50 mM) alone or in combination with 1 nM DOC for 48 and
72 h. The concentrations of DIM and DOC were selected based
on previous studies demonstrating the cytotoxicity in these cells
and other breast cancer cells (Rahman et al. 2007; Ahmad et al.
2011). After 48 h of treatment, cell survival did not decrease sig-
nificantly with 25mM DIM or 1 nM DOC treatment alone,
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whereas increasing DIM concentration to 50 mM decreased the
survival (Figure 1(A,B)). After 72 h, single treatments of DIM or
DOC alone decreased survival in MDA-MB231 but not in Sk-
BR-3 cells. However, when 25 mM of DIM was combined with
1 nM DOC and treated for 48 h, cell survival decreased by 42%
(p 0.05) in MDA-MB231 cells and 59% in Sk-BR-3 cells
(p 0.01) compared to control or either agent alone. The results
of the combination appear to induce synergistic cytotoxicity. The
anti-survival effect of the treatments increased with a longer
incubation time from 48 to 72 h in MDA-MB231 cells but not
in Sk-BR-3 cells, which suggests resistance to the treatments.
Sk-BR-3 cells overexpress HER2 gene, which has been shown to
confer resistance to DOC with respect to cell viability and apop-
tosis (Yu et al. 1996; Carpenter and Lo 2013). HER2 activates
PI3K/Akt/ERK signaling, resulting in proliferation and inhibition
of apoptosis. Combining 50 mM DIM with 1 nM DOC produced
an even greater growth-inhibition (p 0.001) than the combin-
ation of the lower concentration of DIM (25 mM) with DOC in
both cell lines. DIM enhanced the apoptotic effects of DOC.
To determine whether the anti-survival effect of the DIM plus
DOC combination was attributed to an increase in apoptosis, we
measured cell death by annexin V analysis. MDA-MB 231 and
Figure 1. DIM decreased the viability and enhances apoptosis of breast cancer cells treated with docetaxel (DOC). (A) MDA-MB231 and (B) SkBR3 cells were treated
for 48 or 72 h with the indicated concentrations of DIM with or without 1 nM DOC. Cell viability was determined by the MTT assay. (C, D) MDA-MB231 and (E, F)
SkBR3 cells were treated for 48 h, harvested, and subject to annexin V-FITC plus propidium iodide staining. Apoptosis was analyzed by flow cytometry and normalized
to untreated controls. Data are calculated as percent of control and expressed as the mean percentage of control ± SE of 3 independent experiments. p Values were
determined using ANOVA. Bars with different symbols are significantly different (, p< 0.05 vs. control, , p< 0.01 vs. control, 25mM DIM alone, DOC alone;
†, p< 0.001 vs. control, 25mM DIM alone, DOC alone, and 25mM DIM plus DOC).
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Sk-BR-3 cells were treated with DIM, DOC and the combination
of both agents for 48 h. Docetaxel alone induced a significant
increase (p 0.05) in early apoptotic cells in MDA-MB 231 cells
(12.7-fold) (Figure 1(C,D)) but not in Sk-BR-3 cells compared
with control cells. Sk-BR-3 cells did not respond to DOC treat-
ment, which like other HER2 overexpressing cells are resistant to
taxanes (Yu et al. 1996; Carpenter and Lo 2013). The combin-
ation of 25 mM DIM with 1 nM DOC enhanced early apoptosis
to a greater extent than DOC alone in MDA-MB231 cells
(p 0.01) and in Sk-BR-3 cells (p 0.0.05) (Figure 1(E,F)).
Although apoptosis was evident in both cell lines treated with
the combination of 25 mM DIM with 1 nM DOC, the percent of
apoptotic cells was less in the Sk-BR-3 cells (27.6%) than in the
MDA-MB231 cells (45.1%). As mentioned above, this may be
attributed to the increased expression of HER2 in Sk-BR-3 cells,
which confers resistance to apoptosis (Fink and Chipuk 2013).
Increasing the concentration of DIM from 25 to 50 mM or com-
bining it with DOC did not further augment apoptosis in either
cell line, which suggests no additional effects of combining the
higher concentration of DIM (50 mM) with DOC. Western blot
analyses indicated that the protein expression of Bcl-2 decreased
and Bax increased in the combination group for MDA-MB231
cells (Figure 2(A)) and Sk-BR-3 cells (Figure 2(B)). Bcl-2 is an
anti-apoptotic while Bax enhances apoptosis; the decrease ratio
of Bcl-2:Bax promotes apoptosis. Cleavage of PARP, a character-
istic of apoptosis, was also evident with the 25mM DIM plus
1 nM DOC treatment in MDA-MB231 cells (Figure 2(C,D)) and
Sk-BR-3 cells (Figure 2(E,F)) compared to control and or either
agent alone.
DIM in combination with DOC activates JNK, which contrib-
utes to apoptosis. We investigated whether the stress signaling
pathways were involved in mediating the synergistic cytotoxic
effect of the combination treatment. JNK is activated by toxic
chemical treatments, oxidative stress or environmental stress. We
found that the combination of DIM with DOC increased phos-
phorylated JNK in comparison to DIM or DOC treatments alone
with no change in JNK protein (Figure 2(C–F)). These observa-
tions suggest that activation of JNK may be one of the mecha-
nisms mediating the synergistic cytotoxic effects of the
combination. The anti-survival effect of DIM in combination
with DOC is associated with increased ROS production.
Next, we determined whether the increased ROS was involved
in enhancing the cytotoxic effect of the combination of DIM and
DOC. Previous studies have reported that DIM induced apop-
tosis and ROS production in breast cancer cells (Xue et al. 2005;
Gong et al. 2006; Roy et al. 2008). ROS levels were evaluated by
flow cytometry after staining with DCFDA, which is oxidized by
ROS in the presence of endogenous peroxidase to DCF, a highly
fluorescent compound. Figure 3(A,B) shows that after 24 h of
treatment with 25 mM of DIM plus 1 nM DOC, ROS production
increased by 46.5% in the MDA-MB231 and by 29.3% in Sk-BR-
3 cells in comparison with control, 25mM DIM alone and 1 nM
DOC alone. The lower production of ROS in Sk-BR-3 cells may
be attributed to the increased expression of HER2 in these cells.
HER2 overexpression has been shown to decrease ROS produc-
tion by preventing malondialdehyde formation and increasing
SOD activity and glutathione levels (Victorio et al. 2014;
Belmonte et al. 2015). Increasing the concentration of DIM to
50 mM in combination with 1 nM DOC produced a greater
increase in ROS than the combination of the lower concentration
of DIM with DOC. Combining the higher dose of DIM with
DOC also maintained the elevation of ROS after 48 h, which sug-
gests that the increase in ROS is dose-dependent. We also
observed that the elevation in ROS levels observed after 24 h of
treatment with 25 mM DIM plus 1 nM DOC in MDA-MB231
cells was not maintained at 48 h, which may be attributed to the
antioxidant enzymes that remove free radicals such as copper
and zinc (Cu/Zn)SOD, catalase and glutathione peroxidase.
Based on our findings that the effect of the combined treatment
was evident at 24 h and not at 48 h in MDA-MB231 cells, we
elected to measure the effect of the treatments on ROS at 24 h in
Sk-BR-3 cells.
To confirm whether the increased ROS was involved in the
anti-survival and apoptotic response, we pretreated MDA-MB231
cells for 1 h with the antioxidant, NAC or the superoxide scaven-
ger, Tiron and incubated cells for 48 h with 25 mM DIM, 1 nM
DOC or their combination. Figure 4(A,B) illustrates that NAC or
Tiron abolished the anti-survival effect of the drug combination,
which suggests that the cytotoxic effects of the DIM plus DOC
combination can be attributed to ROS. We did not conduct a
similar experiment with the higher dose of DIM (50 mM) in
combination with DOC. Since the pretreatment amounts of
NAC or Tiron are sufficiently high to remove ROS, it is likely
that the results would also indicate that ROS contributes to the
anti-survival effect of the higher dose of DIM with DOC. DIM
in combination with DOC decreased protein expression of
MnSOD and increased NOX2. MnSOD is considered as one of
the most important antioxidant enzymes in the mitochondria
that can contribute to an imbalance of the redox state with
increased production of superoxide (O2
–) and hydrogen peroxide
(H2O2). Mitochondria are a major source of O2
–, which increases
ROS production by reacting with nitric oxide to produce peroxy-
nitrite, a highly reactive compound (Indo et al. 2015).
Superoxide is considered to be the major source of ROS in the
cell. Manganese superoxide dismutase converts O2
– into H2O2,
which is further removed by catalase, glutathione peroxidase and
peroxiredoxins. The accumulation of H2O2 in cells promotes
increased proliferation and tumor growth in cancer cells. We
evaluated whether combining DIM with DOC would alter pro-
tein expression of MnSOD and NADPH oxidases. Figure 5(A)
shows that DIM alone did not alter protein expression of
MnSOD. DOC treatment decreased the expression by 36%
(p< 0.05) compared to control and DIM-treated cells, whereas
the combination of DIM and DOC decreased MnSOD expression
by 54% (p< 0.01) compared to control and DIM treatment.
NADPH oxidases are also the major contributors of ROS pro-
duction and regulate proliferation and cell death (Block and
Gorin 2012). DIM in combination with DOC produced a signifi-
cant increase (47%, p 0.01) in NOX2 protein expression com-
pared with the control, DIM alone and DOC alone groups
(Figure 5(B)). NOX4 protein expression was not altered, which
may suggest that it is not involved in the enhanced production
of ROS induced by the combination of DIM with DOC.
Discussion
Besides its toxic effects in treating breast cancer, resistance to
DOC occurs because the drug is not efficient in blocking acti-
vated survival pathways. Using nontoxic plant compounds to
improve DOC efficiency and reduce toxic side effects is an
attractive strategy. In this study, we present data supporting the
premise that DIM improved the anti-cancer effects of DOC in
breast cancer cells. Other reports found that DIM increased the
effectiveness of DOC in lung cancer (Ichite et al. 2009) and
paclitaxel in gastric cancer (Jin et al. 2015). The enhanced
chemo-sensitivity of DIM is not limited to the taxanes. Several
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reports have demonstrated that DIM potentiated the effects of
cisplatin in ovarian cancer (Kandala and Srivastava 2012) and
gemcitabine in pancreatic cancer (Banerjee et al. 2009). Recently
DIM has been shown to improve sensitivity of breast cancer cells
to ionizing radiation (Wang et al. 2016), which further demon-
strates the therapeutic potential of DIM in cancer treatment.
The combination of DIM plus DOC targeted ROS, Bcl2, Bax
and NOX2, which were not altered by either treatment alone.
Cleavage of PARP was observed in cells treated with DIM or
DOC and this effect was significantly enhanced by the combin-
ation of both compounds. DIM alone and DOC alone increased
protein expression of phosphorylated JNK to a similar extent but
the combination of both treatments produced a much greater
increase, which occurred in a synergistic manner.
In the present investigation, we observed that the combin-
ation treatment increased ROS after 24 h, resulting in apoptosis
at 48 h. Since excessive production of ROS contributes to apop-
tosis, we evaluated whether the elevation in ROS after 24 h of
Figure 2. DIM in combination with DOC altered protein expression of Bcl2 and Bax, induced PARP cleavage, and activated JNK. Cells were treated with 25mM DIM,
1 nM DOC, or 25mM DIM plus 1 nM DOC for 48 h and probed with antibodies to Bcl2, Bax, PARP, phosphorylated JNK, and JNK. Blots were stripped and reprobed
with antibody to GAPDH to verify equal loading. Bcl2 and Bax protein expression are shown in (A) MDA-MB231 cells and (B) SkBR3 cells. PARP, phosphorylated JNK,
and JNK are shown in MDA-MB231 cells (C, D) and SkBR3 cells (E, F). p Values were determined using ANOVA. Bars represent mean scanning units ± SE of three differ-
ent experiments. Bars with different symbols are significantly different (, p< 0.05 vs. control; , p< 0.05 vs. control, 25mM DIM alone; †, p< 0.05 vs. control, 25mM
DIM, and DOC).
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Figure 3. DIM in combination with DOC stimulates ROS production in DOC treated breast cancer cells. (A) MDA-MB231 and (B) SkBR3 cells were treated for 24 or
48 h with the indicated concentrations of DIM with or without 1 nM DOC and analyzed for DHR fluorescence by flow cytometer. Bars represent relative percentage of
surviving cells in four independent experiments. p Values were determined using ANOVA. Bars with different symbols are significantly different (, p< 0.05 vs. control,
25mM DIM alone, and DOC alone; , p< 0.05 vs. control, 25mM DIM alone, DOC alone, 25mM DIM plus DOC, and 50mM DIM).
Figure 4. Pretreating MDA-MB231 cells NAC or Tiron abrogated the anti-survival effect of the DIM plus DOC combination. Cells were pretreated for 1 h with either (A)
5mM NAC or (B) 1mM Tiron and incubated for 48 h. Viability was determined by MTT assay. Bars represent relative percentage of surviving cells in four independent
experiments. p Values were determined using ANOVA (, p< 0.01 vs. control, NAC or Tiron alone, and 25mM DIM plus DOC plus NAC).
Figure 5. The combination of DIM and DOC decreased MnSOD and increased NOX2 protein expression. MDA-MB231 cells were treated for 48 h with 25mM DIM with
or without 1 nM DOC. Cell proteins were detected by Western blot with antibodies to (A) MnSOD, (B) NOX2, and NOX4. Blots were stripped and reprobed with anti-
body to GAPDH to verify equal loading. Blots were quantified by Image J and normalized to GAPDH. Bars represent mean scanning units ± SE of three different experi-
ments. p Values were determined using ANOVA (, p< 0.05 vs. control and 25mM DIM alone; , p< 0.01 vs. control, 25mM DIM alone, and DOC alone).
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treatment with DIM plus DOC led to reduced cell survival. The
antioxidants NAC or Tiron abrogated the anti-survival effect of
the DIM plus DOC combination, which suggests that the
increased ROS observed at 24 h may trigger signaling events that
promote the decreased cell survival observed with the combined
treatment at 48 h.
Several studies have demonstrated that ROS mediates apop-
tosis through downstream activation of p38 MAPK and JNK
(Benhar et al. 2002; Shen and Liu 2006; Zhu et al. 2014). We
observed that the increase in ROS production with the combin-
ation treatment was associated with activation of JNK. Previous
studies have demonstrated that DIM increased ROS production
and induced JNK and p38 signaling in breast cancer cell lines
(Xue et al. 2005; Gong et al. 2006; Roy et al. 2008). The early
increase in ROS and subsequent activation of p38 or JNK may be
sufficient to induce apoptosis after 48 h of treatment without sus-
taining the elevation in ROS. Further studies are needed to inves-
tigate the role of ROS-mediated activation of p38 and JNK in the
enhanced apoptotic effect of the DIM plus DOC combination.
The increased accumulation of ROS results from the imbal-
ance of the antioxidant scavenger enzymes such as MnSOD that
remove ROS and the NOX system that produces ROS.
Superoxide is the major source of ROS and, if not cleared by
MnSOD, can lead to additional free radicals leading to DNA
damage and cell death such as apoptosis, autophagy and necrosis
(Indo et al. 2015). This is the first study to find that the DIM
plus DOC combination decreases MnSOD protein expression.
We found that the expression of MnSOD decreased to a greater
extent with the combination treatment than with DIM or DOC
alone, which was associated with increased ROS. Highly invasive
MDA-MB231 cells and HER2 positive Sk-BR-3 cells have ele-
vated levels of MnSOD compared to ERþ breast cancer cell lines
(Kattan et al. 2008). Suppression of MnSOD expression with
antisense RNA increased H2O2 and reduced proliferation and
tumor growth (Kattan et al. 2008). Their findings support the
premise that suppression of MnSOD by the combination treat-
ment is a contributory factor to the accumulation of ROS, apop-
tosis and decreased tumor growth. Additional studies will be
important to investigate the regulatory role of MnSOD in
increasing ROS with the combination treatment.
The mechanisms by which the DIM plus DOC combination
regulate MnSOD are not known. A previous study has demon-
strated that the transcription factors, Sp1 and NF-jB are
involved in the regulation of MnSOD (Becuwe et al. 2014). DIM
and DOC have been shown to increase apoptosis by inactivating
NF-jB (Rahman et al. 2007). Since the promoter for MnSOD
has binding sites for these transcription factors, the inactivation
of NF-jB or downregulation of Sp1 could explain the decrease
in MnSOD expression.
NOX2 is expressed in breast cancer cells (Satooka and Hara-
Chikuma 2016). However, the role of NOX2 in mediating the
effects of the chemotherapeutic drugs in breast cancer has not
been explored. This is the first study to show that DIM in com-
bination with DOC increased NOX2 expression along with ele-
vating ROS, while the individual compounds had no effect. A
recent study demonstrated that the combination of erlotinib with
ampelopsin induced apoptosis and increased ROS production
through the up-regulation of NOX2 (Hong et al. 2017). Further
studies are needed to investigate the role of NOX2 in ROS
production in breast cancer. Inhibiting NOX2 with siRNA may
provide insight as to whether the increase in NOX2 contributes
to the accumulation of ROS induced by the DIM plus DOC
combination.
In summary, we found that DIM significantly increases the
sensitivity of triple negative and HER2 positive breast cancer cell
lines to DOC by decreasing cell survival and inducing apoptosis
in a synergistic manner. The anti-survival and pro-apoptotic
effect of combining DIM with DOC was correlated with
decreased Bcl2, increased Bax, activation of JNK and cleavage of
PARP. This study is also the first to show that the combination
treatment induced ROS. Pretreating the cells with NAC or Tiron
abrogated the cytotoxic effect of the DIM plus DOC combin-
ation, which suggests that ROS mediates the anti-survival and
apoptotic effects of the treatment.
Our findings also show that the induction of ROS observed
with the combination of DIM and DOC was associated with
decreased protein expression of MnSOD and increased NOX2.
All together, the data obtained from this study suggest a poten-
tial benefit for breast cancer patients and provide a rationale for
further clinical investigation of DIM with chemotherapy for
breast cancer treatment.
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